Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every living cell, playing essential roles in cellular metabolism, DNA repair, and gene expression regulation. Over the past two decades, research has revealed that NAD+ levels decline substantially with age in various organisms, raising important questions about whether this decline contributes to age-related physiological changes.
The study of NAD+ metabolism has become one of the most active areas in aging biology research. Understanding how NAD+ functions, why it declines, and what effects this decline may have provides valuable insight into fundamental aging processes. This article examines NAD+ biochemistry, the evidence for age-related decline, and the current state of research on NAD+ and aging.
NAD+ is a dinucleotide—a molecule consisting of two nucleotides joined through their phosphate groups. Its structure allows it to function as an electron carrier and as a substrate for several classes of enzymes critical to cellular function.
In its role as an electron carrier, NAD+ participates in hundreds of redox reactions throughout cellular metabolism. During these reactions, NAD+ accepts two electrons and a proton (H+) to become NADH (the reduced form). This conversion is central to cellular energy production.
The glycolysis pathway, which breaks down glucose, generates NADH from NAD+. The citric acid cycle (also called the Krebs cycle) produces additional NADH. This NADH then delivers electrons to the electron transport chain in mitochondria, where they drive ATP synthesis. After delivering electrons, NADH is oxidized back to NAD+, allowing the cycle to continue.
This regeneration is crucial—cells contain relatively limited pools of NAD+/NADH, which must be continuously cycled. If NAD+ becomes depleted or the NAD+/NADH ratio becomes severely imbalanced, cellular energy metabolism can be impaired.
Beyond electron transfer, NAD+ serves as a substrate (consumed reactant) for several important enzyme families:
When these enzymes use NAD+, they consume it—breaking it down to nicotinamide and ADP-ribose (or related compounds). This consumption creates continuous demand for NAD+ synthesis to maintain cellular pools.
Cells can synthesize NAD+ through multiple pathways, using different precursor molecules. Understanding these pathways is important for comprehending how NAD+ levels are maintained and why they might decline with age.
The de novo pathway starts with the amino acid tryptophan and builds NAD+ through a series of enzymatic steps. This pathway primarily operates in the liver and can provide NAD+ when dietary precursors are scarce. However, research suggests this pathway may not be the primary source of NAD+ in most tissues under normal conditions.
Most NAD+ biosynthesis in mammalian cells occurs through salvage pathways that recycle breakdown products back into NAD+. The primary salvage pathway uses nicotinamide (NAM)—produced when sirtuins, PARPs, and other enzymes consume NAD+.
The rate-limiting enzyme in this salvage pathway is nicotinamide phosphoribosyltransferase (NAMPT). NAMPT converts nicotinamide to nicotinamide mononucleotide (NMN), which is then converted to NAD+ by NMN adenylyltransferases (NMNATs).
Another pathway uses nicotinic acid (NA, also called niacin or vitamin B3) as a precursor. NA is converted to nicotinic acid mononucleotide (NAMN) and then to NAD+ through subsequent steps. This pathway appears particularly important in the liver.
Research has also examined other NAD+ precursors, including:
These alternative precursors have become subjects of research interest because they can potentially bypass certain regulatory steps in NAD+ biosynthesis.
Multiple studies across various species have documented declining NAD+ levels with age, though the magnitude and tissue specificity vary across reports.
Research in rodents has consistently shown age-related NAD+ decline in multiple tissues. A landmark 2013 study found that NAD+ levels in skeletal muscle of 32-month-old mice (very old for mice) were approximately 50% lower than in 6-month-old young adult mice. Similar declines have been reported in liver, adipose tissue, heart, and brain, though the magnitude varies by tissue and study.
Studies in other model organisms support these findings. Research in Caenorhabditis elegans (roundworms) and Drosophila (fruit flies) has also documented NAD+ decline during aging. The consistency across evolutionarily distant species suggests that NAD+ decline may be a conserved feature of the aging process.
Measuring NAD+ levels in living humans presents technical challenges, as most tissues cannot be easily sampled. Research has primarily examined:
Overall, while human data is more limited than animal data, available evidence generally supports the occurrence of age-related NAD+ decline in humans as well.
The reported magnitude of NAD+ decline varies considerably across studies, ranging from approximately 30% to over 50% reduction from young adulthood to old age, depending on the tissue examined and measurement methods used.
Research suggests the decline begins relatively early—some studies report detectable NAD+ reduction by middle age rather than only in advanced age. The decline appears progressive rather than sudden, accumulating gradually over decades.
Why does NAD+ decline with age? Research has identified several contributing mechanisms, though their relative importance likely varies by tissue and context.
Some studies report reduced expression or activity of biosynthetic enzymes with age. Research has found decreased NAMPT (the rate-limiting salvage pathway enzyme) expression in aged tissues in some animal studies, potentially reducing NAD+ production capacity.
However, findings are not entirely consistent across all studies and tissues, suggesting that decreased biosynthesis may contribute to NAD+ decline in some contexts but may not be the sole or primary mechanism.
Research has also examined whether increased NAD+ consumption contributes to declining levels. Several NAD+-consuming enzymes show altered activity with age:
A 2016 study reported that CD38 levels increase substantially with age in mice, and that this increase contributes to NAD+ decline. Mice lacking CD38 showed attenuated age-related NAD+ decline, supporting a causal role for CD38 in at least some contexts.
Some research suggests that the efficiency of NAD+ recycling through salvage pathways may decline with age. This could result from multiple factors including reduced enzyme expression, altered cellular localization of biosynthetic enzymes, or changes in substrate availability.
Much of the interest in NAD+ and aging stems from its relationship with sirtuins—proteins that regulate various cellular processes relevant to aging and metabolism.
Sirtuins are NAD+-dependent deacetylases that remove acetyl groups from lysine residues on target proteins. This reaction consumes NAD+, breaking it down to nicotinamide and O-acetyl-ADP-ribose. Because sirtuins require NAD+ as a substrate, their activity depends on cellular NAD+ availability.
Mammals have seven sirtuins (SIRT1-7) with different cellular locations and functions:
Research in model organisms has linked sirtuins to lifespan regulation. Increased activity of Sir2 (the yeast sirtuin) extends lifespan in budding yeast. Overexpression of sirtuins has shown lifespan-extending effects in some studies in worms and flies, though not all studies have replicated these findings.
In mammals, the relationship between sirtuins and longevity is complex. While sirtuins influence many processes relevant to aging—including metabolism, stress resistance, inflammation, and DNA repair—whether increasing sirtuin activity extends mammalian lifespan remains an active research question.
The central question is: Does age-related NAD+ decline limit sirtuin activity, and if so, does this contribute to aging-related dysfunction?
Research has shown that NAD+ levels can influence sirtuin activity. When NAD+ is depleted experimentally, sirtuin activity decreases. Conversely, increasing NAD+ levels can enhance sirtuin activity in various experimental contexts.
Studies in aged mice given NAD+ precursors have reported increased sirtuin activity along with various physiological improvements, supporting the hypothesis that NAD+ decline may limit sirtuin function during aging. However, whether these effects occur primarily through sirtuins or through other NAD+-dependent pathways remains an area of ongoing investigation.
Another critical function linking NAD+ to aging involves DNA repair, mediated primarily through PARPs.
PARPs detect DNA damage and respond by adding chains of ADP-ribose units (derived from NAD+) onto target proteins. This modification serves as a signal that recruits DNA repair machinery to damage sites. PARP1, the most abundant family member, plays a particularly important role in repairing single-strand DNA breaks.
PARP activity is essential for genomic stability. Cells lacking functional PARP1 show increased sensitivity to DNA-damaging agents and accumulate more DNA damage. However, excessive PARP activation can deplete cellular NAD+ pools, potentially impairing cellular function.
The relationship between DNA damage, PARP activation, and NAD+ creates a potential double-edged sword in aging. As DNA damage accumulates with age, increased PARP activation to repair this damage could deplete NAD+ pools. This NAD+ depletion might then impair other NAD+-dependent processes, including energy metabolism and sirtuin function.
Research has shown that severe PARP activation can cause cellular NAD+ depletion and energy crisis. Whether chronic, moderate PARP activation contributes to gradual NAD+ decline during normal aging remains under investigation.
Numerous studies have examined whether restoring NAD+ levels in aged animals produces beneficial effects. This research has used various NAD+ precursors including NMN, NR, and nicotinamide.
Research in aged mice given NMN or NR has reported various metabolic improvements:
These studies generally use pharmacological doses of precursors substantially higher than typical dietary intake of B3 vitamins.
Some studies have reported improvements in physical performance measures in aged rodents given NAD+ precursors, including enhanced endurance capacity and muscle function. However, findings are not entirely consistent across all studies, with some showing modest or no effects on these parameters.
Research has examined effects of NAD+ restoration on cardiovascular function in aged animals. Some studies report improvements in vascular function, cardiac performance, and arterial elasticity, though again, results vary across different experimental models and conditions.
Importantly, most studies have not examined whether NAD+ precursor supplementation extends lifespan in normally aging animals. A few studies have reported lifespan extension in certain disease models or under specific conditions, but evidence for lifespan extension in healthy aging animals remains limited.
Translation of animal findings to humans remains in relatively early stages. Human studies of NAD+ precursors have primarily focused on safety, bioavailability, and preliminary physiological effects.
Clinical trials have established that NR and NMN supplementation can increase blood NAD+ levels in humans, with both precursors appearing generally safe at doses studied (typically ranging from 250-1000 mg per day for durations up to several months).
However, whether oral supplementation increases NAD+ levels in specific tissues of interest (muscle, brain, liver, etc.) in humans remains less clear, as these tissues cannot be easily sampled.
Small clinical trials have examined various outcomes:
Most human studies to date have been small (often fewer than 50 participants), relatively short-term (weeks to months), and have examined specific populations rather than broad healthy aging cohorts. Results have been mixed, with some showing modest effects on certain outcomes while others find minimal changes.
Current human research faces several limitations:
NAD+ decline represents one of the most well-documented biochemical changes that occurs with aging across multiple species. The molecule's central roles in energy metabolism, DNA repair, and regulation of sirtuins and other enzymes make it a compelling target for aging research.
Research in animal models has demonstrated that restoring NAD+ levels can improve various markers of metabolic and physiological function in aged animals, supporting the hypothesis that NAD+ decline contributes to certain aspects of aging-related dysfunction. These findings have generated substantial interest in NAD+ precursors as potential interventions for healthy aging.
However, important questions remain, particularly regarding translation to humans. While supplementation with NAD+ precursors can increase blood NAD+ levels in humans and appears safe in studies conducted to date, whether this produces meaningful improvements in human healthspan or addresses age-related dysfunction requires additional research. Long-term studies in diverse human populations will be needed to determine the ultimate clinical significance of NAD+ restoration strategies.
Understanding NAD+ metabolism and its changes with age provides valuable insight into fundamental aging processes. As research continues, it will clarify whether targeting NAD+ decline represents a viable strategy for promoting healthy aging in humans.